Abstract
In patients with high cholesterol and at risk of cardiovascular disease, inhibitors of PCSK9 are useful in lowering lipid levels but must be dosed regularly. A recent study in Nature by Munsunuru and colleagues explores the possibility of permanently disrupting PCSK9 expression via in vivo CRISPR gene editing in non-human primates, with long-lasting reductions in LDL cholesterol.